Subrata Bhattacharyya
Overview
Explore the profile of Subrata Bhattacharyya including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
104
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Harper J, Baldwin H, Choudhury S, Rai D, Ghosh B, Aman M, et al.
J Drugs Dermatol
. 2024 Apr;
23(4):216-226.
PMID: 38564399
Background: Multiple treatment options exist for the management of moderate-to-severe acne. However, the comparative effectiveness (efficacy/safety) of moderate-to-severe acne treatments has not been systematically examined. Methods: A systematic literature review...
2.
Bhattacharyya S, Hariprasad S, Albini T, Dutta S, John D, Padula W, et al.
Value Health
. 2022 Sep;
25(10):1705-1716.
PMID: 36055922
Objectives: Suprachoroidal injection of triamcinolone acetonide is the first Food and Drug Administration-approved treatment for macular edema associated with uveitis. A cost-effectiveness analysis was performed comparing this treatment with best...
3.
Hariprasad S, Joseph G, Gagnon-Sanschagrin P, Serra E, Bhattacharyya S, Bedard J, et al.
BMJ Open Ophthalmol
. 2021 Nov;
6(1):e000896.
PMID: 34786486
Objective: To describe patient characteristics and healthcare costs associated with uveitic macular oedema (UME) in US clinical practices from a commercial payer's perspective. Methods And Analysis: The IBM MarketScan Commercial...
4.
Stein E, Xie J, Duchesneau E, Bhattacharyya S, Vudumula U, Ndife B, et al.
Pharmacoeconomics
. 2018 Nov;
37(2):239-253.
PMID: 30382485
Objectives: The aim of this study was to assess the cost effectiveness of midostaurin + cytarabine + daunorubicin (midostaurin arm) versus placebo + cytarabine + daunorubicin (placebo arm) in the...
5.
Ojha B, Bajracharya D, Bhattacharyya S, Baral R, Roy S, Singh S, et al.
JNMA J Nepal Med Assoc
. 2018 Nov;
56(211):705-707.
PMID: 30381770
Glandular odontogenic cyst is rare phenomenon with 0.012% to 0.03% frequency of all jaw cysts and worldwide prevalence of 0.17%. Diagnosis of Glandular odontogenic cyst, well known for its aggressive...
6.
Stein E, Yang M, Guerin A, Gao W, Galebach P, Xiang C, et al.
Health Qual Life Outcomes
. 2018 Sep;
16(1):193.
PMID: 30241538
Background: Preference valuations of health status are essential in health technology and economic appraisal. This study estimated utilities for treatment-related health states of acute myeloid leukemia (AML) and disutilities of...
7.
Mistry R, Suri G, Young K, Hettle R, May J, Brixner D, et al.
Curr Med Res Opin
. 2018 Jul;
34(12):2143-2150.
PMID: 30032697
Objectives: The combination of a cyclin-dependent kinase 4 and 6 (CDK 4/6) inhibitor with the aromatase inhibitor letrozole is a safe and effective alternative to letrozole monotherapy for first-line hormone...
8.
Mistry R, May J, Suri G, Young K, Brixner D, Oderda G, et al.
J Manag Care Spec Pharm
. 2018 May;
24(6):514-523.
PMID: 29799329
Background: U.S. regulatory approvals of the cyclin-dependent kinase 4 and 6 (CDK 4/6) inhibitors ribociclib and palbociclib as add-ons to letrozole greatly enhance the prospects for treating postmenopausal women with...
9.
Gustavsson A, Green C, Jones R, Forstl H, Simsek D, de Reydet de Vulpillieres F, et al.
Alzheimers Dement
. 2017 Jan;
13(3):312-321.
PMID: 28063281
Available data and models for the health-economic evaluation of treatment in Alzheimer's disease (AD) have limitations causing uncertainty to decision makers. Forthcoming treatment strategies in preclinical or early AD warrant...
10.
Li N, Yang X, Fan L, Totev T, Guerin A, Chen L, et al.
J Med Econ
. 2016 Nov;
20(4):328-336.
PMID: 27841717
Objective: To evaluate the cost-effectiveness of second-line nilotinib vs dasatinib among patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP) who are resistant or intolerant to imatinib,...